LDN for Long COVID: Fatigue, Brain Fog, and the GLP-1 Question

What four observational studies suggest, why randomized evidence still matters, and how metabolic treatment should be coordinated with post-viral symptoms

Fatigue that does not lift with rest. Trouble finding words or following a conversation. A delayed crash after an ordinary errand, work meeting, or light exercise. Long COVID can affect daily life through a shifting combination of symptoms, and there is still no single treatment that works for everyone.

Low Dose Naltrexone, commonly called LDN, has become one of the off-label medications discussed for fatigue, brain fog, sleep disruption, pain, and reduced function. In July 2026, researchers published the first systematic review and meta-analysis focused on LDN for Long COVID. The pooled findings were encouraging enough to support better trials, but not strong enough to establish efficacy.

The review found four observational pre-post studies involving 155 participants. It found improvement signals for fatigue, brain fog, sleep, pain, and daily function. It found no randomized controlled trial results, rated the evidence as low certainty, and concluded that controlled trials are needed. Read the 2026 systematic review.

Direct answer: LDN is not FDA approved or established as a treatment for Long COVID. Four small observational studies have reported improvement signals, including fatigue and brain fog, but no published randomized result has yet shown that LDN outperforms placebo, prevents post-exertional crashes, or changes the underlying condition. GLP-1 medications may be appropriate for a separate metabolic indication, not as proven Long COVID therapy.

Explore Patient-Specific Options With Scripx

Interested in a patient-specific LDN prescription? View Scripx Pharmacy's Low Dose Naltrexone information and ask a licensed prescriber whether an off-label evaluation is appropriate for a clearly defined symptom goal.

Evaluating GLP-1 therapy for a separate metabolic goal? Explore Scripx Pharmacy's medically supervised weight-management services.

Already have a prescription or need formulation guidance? Contact the Scripx Pharmacy team or learn about Scripx compounding services.

All prescription medications require evaluation by a licensed healthcare provider. LDN use for Long COVID is off label. Compounded medications are not FDA approved. Persistent or worsening symptoms require appropriate medical evaluation, and emergency symptoms require urgent care.

Ready to Get Started?

Explore available treatment options and complete a secure health questionnaire for provider review.

View Products & Start Your Order →

Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.

What Did Matt Damon Actually Do?

In a January 2026 interview with Andy Cohen, Damon described a 90-day plan completed with his wife and under the direction of his doctor. The plan excluded five categories:

Long COVID Is More Than Persistent Fatigue

Long COVID is a chronic condition that occurs after SARS-CoV-2 infection and may involve symptoms that persist, resolve and return, or develop over time. More than 200 symptoms have been reported. Frequently described problems include fatigue, difficulty thinking or concentrating, sleep disturbance, pain, shortness of breath, palpitations, dizziness, digestive symptoms, and changes in smell or taste.

The Centers for Disease Control and Prevention emphasizes a patient-centered approach: complete an appropriate evaluation, validate symptoms, tailor treatment to the person's most burdensome problems, and connect patients with care and support. There is no laboratory test that can by itself confirm or rule out Long COVID. Review CDC Long COVID clinical guidance.

Several outcomes that sound similar are not interchangeable:

1. Less fatigue does not necessarily mean normal stamina.

2. Better concentration does not necessarily mean recovery of work capacity.

3. A better sleep score does not prove that post-exertional malaise has resolved.

4. More activity on a good day does not prove that a delayed crash will not follow.

5. Symptom improvement does not establish that a medication modifies the underlying disease process.

That distinction should shape every discussion of the LDN evidence.

Post-Exertional Malaise Changes the Safety Conversation

Post-exertional malaise, or PEM, is a worsening of symptoms after physical, cognitive, or emotional effort that previously would have been tolerated. The worsening can begin 12 to 48 hours after the activity and last for days or weeks, according to CDC guidance. Review common Long COVID signs and symptoms.

PEM is not simply ordinary tiredness after exercise. It can involve a delayed increase in fatigue, cognitive difficulty, pain, flu-like symptoms, sleep disruption, dizziness, or other symptoms. A person may feel capable during an activity and still experience a marked decline the next day.

This is why a generic instruction to exercise through fatigue can be inappropriate. Activity plans should account for the individual's symptoms and response. Pacing generally means balancing activity and rest to reduce the risk of exceeding the person's current energy limits. It is not a cure, and it is not the same as permanent inactivity.

No adequate evidence shows that LDN prevents PEM. If a person feels somewhat better after starting a medication, suddenly increasing activity may make the treatment difficult to assess and may provoke a delayed setback. Tracking both activity and symptoms for the following 48 hours provides more useful information than rating energy only in the moment.

What Is Low Dose Naltrexone?

Naltrexone is an opioid receptor antagonist. FDA-approved oral naltrexone is used for specific alcohol- and opioid-related indications, commonly as a 50 mg tablet. Low Dose Naltrexone describes clinician-directed use at substantially lower doses for purposes outside the approved labeling.

There is no FDA-defined LDN product and no FDA-approved naltrexone indication for Long COVID, fatigue, brain fog, PEM, dysautonomia, or weight loss. A patient-specific compounded low-dose formulation is also not FDA approved.

Researchers have proposed several reasons to study LDN in post-viral illness, including effects involving opioid signaling, immune activity, microglia, inflammatory pathways, and ion-channel function. A proposed mechanism can justify a clinical trial. It cannot show that patients feel better, return to work, avoid crashes, or recover.

For more background, read what Low Dose Naltrexone is, including its uses, evidence, safety, and compounding.

What Did the 2026 Systematic Review Find?

The 2026 systematic review searched the literature through May 5, 2026. It identified four observational pre-post studies from the United States and Ireland, with 155 participants in total. Doses ranged from 1 to 6 mg per day.

When the investigators pooled before-and-after scores, they reported improvement signals for:

• Fatigue, standardized mean difference, or Hedges' g, of -0.74

• Brain fog, g of -0.53

• Sleep, g of -0.60

• Pain, g of -0.93

• Daily function, g of -0.93

These values describe change within the treated groups. They do not show how much improvement would have occurred without LDN. Long COVID symptoms can fluctuate. Participants may also change sleep, activity, nutrition, other medications, or supportive care during follow-up. Expectation and reporting effects can influence subjective outcomes. People who tolerate a treatment and remain in follow-up may differ from those who stop.

The review found no randomized controlled trials. It rated the evidence as low certainty because the studies were small, heterogeneous, and vulnerable to bias. Two studies assessed safety and reported no serious adverse events, but the available sample is not large enough to characterize uncommon risks.

The responsible summary is straightforward: the direction of the signal supports research, while the study design prevents a causal conclusion.

LDN for Long COVID: Evidence at a Glance

Evidence question	What has been reported	What remains unproven
Direct clinical evidence	Four observational pre-post studies included 155 participants	A published randomized result showing benefit beyond placebo or usual care
Fatigue	Pooled before-and-after scores improved	Reliable effect size, durability, and which patients benefit
Brain fog	Pooled self-reported brain-fog scores improved	Objective cognitive benefit, return-to-work improvement, or restored baseline function
Sleep, pain, and function	Improvement signals were reported	Durable recovery, prevention of relapse, or independence from other care changes
Post-exertional malaise	PEM is clinically important in Long COVID	Prevention of delayed post-exertional symptom worsening
Disease modification	Mechanistic hypotheses and a small ion-channel study exist	Viral clearance, immune normalization, prevention of organ damage, or cure
GLP-1 crossover	Approved therapy may address a separate obesity, diabetes, sleep-apnea, or cardiovascular indication	GLP-1 therapy as a proven treatment for fatigue, brain fog, PEM, or Long COVID
LDN plus GLP-1	Both may be considered for separate goals after individualized review	A proven combination for Long COVID recovery or enhanced weight loss

What the Individual Studies Can and Cannot Tell Us

The 2022 Irish pre-post study

An interventional pre-post study enrolled 52 people with post-COVID symptoms. Thirty-eight were known to have started LDN, and 36 completed a two-month questionnaire. The planned dose was 1 mg during the first month and 2 mg during the second.

Participants reported improvement in six of seven measured areas, including recovery, daily activities, energy, pain, concentration, and sleep. Two people stopped because of diarrhea and fatigue. There was no randomized placebo group, and the study was not blinded. Review the 2022 study.

The study shows that a low-dose regimen was feasible for many participants and that improvement was reported during treatment. It does not establish that LDN caused the improvement.

The 2024 post-COVID clinic cohort

A 2024 observational analysis examined the first 108 people treated at a post-COVID clinic. Compared with physical therapy alone, people receiving LDN had a reported relative hazard of improvement of 5.04, with a 95% confidence interval from 1.22 to 20.77. Fatigue and pain were among the symptoms reported to improve. Review the clinic cohort.

The estimate is attention-grabbing, but the confidence interval is extremely wide. Treatment was not randomly assigned, so differences in patient selection, timing, coexisting conditions, other treatments, follow-up, or clinician judgment may have influenced the result. The authors appropriately called for randomized trials.

The LDN plus NAD+ pilot

A 2024 pilot followed 36 participants who received 4.5 mg LDN per day plus nicotinamide adenine dinucleotide, or NAD+, delivered by iontophoresis patches. Average SF-36 quality-of-life scores increased from 36.5 to 52.1, and average Chalder fatigue scores decreased from 25.9 to 17.4 over 12 weeks. Fifty-two percent were classified as responders. Skin irritation from the patches was reported in 25%. Review the LDN plus NAD+ study.

Because two interventions were given together and there was no placebo group, the study cannot isolate the effect of LDN. The small sample, responder definition, self-reported outcomes, and author affiliations also belong in the interpretation.

The pooled evidence

Combining small studies can estimate the direction and consistency of a signal, but pooling does not repair the absence of randomization. If each study is susceptible to natural symptom fluctuation, expectation effects, attrition, and co-intervention bias, the meta-analysis remains susceptible to those problems.

The new review is valuable because it gathers the available evidence, quantifies the signals, and makes the evidence gap explicit. It should not be marketed as proof that LDN works for Long COVID.

What Does the TRPM3 Study Mean?

A 2025 laboratory study compared natural killer cells from nine people with Long COVID taking LDN, nine untreated people with Long COVID, and nine healthy controls. Participants taking LDN used 3 to 4.5 mg per day. The researchers reported restoration of transient receptor potential melastatin 3, or TRPM3, ion-channel currents in the treated group. Review the TRPM3 study.

That is a mechanistic finding, not a clinical efficacy result. The study was small and nonrandomized. It did not establish that LDN improved fatigue, cognition, PEM, daily function, or recovery. A laboratory measure can help researchers formulate a hypothesis and select future biomarkers. It cannot substitute for a blinded trial measuring patient-important outcomes.

Are Randomized Trials Available Yet?

Randomized, blinded trials are designed to reduce several biases that affect uncontrolled symptom studies. They are especially important in Long COVID because symptoms can fluctuate and because no single patient-reported measure captures the entire condition.

Two registered studies are particularly relevant:

• NCT05430152: A Canadian phase 2 randomized, double-blind, placebo-controlled trial of LDN for post-COVID fatigue syndrome enrolled 160 participants and studied doses from 1 to 4.5 mg for 16 weeks. The registry reports study completion in February 2026. The 2026 systematic review, whose search ran through May 5, did not identify a published randomized result. Review the trial record and published protocol.

• NCT06366724, the LIFT trial: This phase 2 double-blind factorial study is evaluating LDN, pyridostigmine, both, or placebo in people with ME/CFS and orthostatic intolerance. People whose illness began with COVID-19 may qualify if they meet the study criteria. The registry lists an estimated study completion in November 2026. Review the LIFT trial.

A completed registry entry is not the same as a published result. Until results are posted or peer reviewed, it is not possible to know whether a trial found benefit, no benefit, harm, or an inconclusive outcome.

Does Symptom Improvement Mean Recovery?

No. Symptom improvement can be meaningful without being complete recovery.

In a 2026 cohort of 3,590 people with Long COVID, fatigue was reported by 78.7% and brain fog by 53.5%. Only 33.4% reported recovery to more than 75% of their pre-COVID health. Greater fatigue and dysautonomia were associated with poorer recovery. Review the cohort study.

This cohort does not evaluate LDN. It illustrates why a study should measure more than whether one symptom improved. Useful outcomes may include:

• Fatigue severity and interference

• Cognitive symptoms and performance where appropriate

• Frequency and duration of PEM

• Orthostatic symptoms and heart-rate response

• Sleep quality

• Pain interference

• Ability to complete basic and instrumental daily activities

• Work or school participation

• Overall health relative to the pre-COVID baseline

• Adverse effects and treatment discontinuation

An individualized off-label trial should define the target outcome before the medication starts. Otherwise, normal symptom variation can be mistaken for benefit or failure.

A Practical Monitoring Plan for an Off-Label LDN Trial

If a prescriber determines that an LDN trial is reasonable, a structured plan makes the decision more informative. It should include:

1. One or two priority outcomes. Examples include fatigue interference, cognitive stamina, sleep quality, or pain, rather than the vague goal of “feeling better.”

2. A baseline period. Record symptoms, activity, PEM, sleep, orthostatic symptoms, and important co-interventions before the first dose.

3. A dosing plan. Dose and titration should be individualized by the prescriber and pharmacist. More is not automatically better.

4. A stable activity strategy. Avoid interpreting a burst of activity as recovery, and monitor the following 12 to 48 hours for PEM.

5. A reassessment date. Decide when benefit, tolerability, and continuation will be reviewed.

6. A stop rule. Define what would prompt a dose change, pause, or discontinuation.

7. Continued evaluation. Do not let an off-label medication trial replace assessment for anemia, thyroid disease, sleep disorders, cardiopulmonary problems, dysautonomia, medication effects, depression, or another treatable contributor when clinically indicated.

LDN can cause adverse effects. Reported issues in the broader literature include vivid dreams, sleep disturbance, headache, gastrointestinal symptoms, and fatigue. Individual tolerability varies. New, severe, or worsening symptoms should be reviewed rather than automatically attributed to Long COVID.

Where Do GLP-1 Medications Fit?

Semaglutide and tirzepatide have not been established as treatments for Long COVID. They should not be presented as proven therapies for fatigue, brain fog, PEM, dysautonomia, or post-viral recovery.

The legitimate crossover is a separate indication. A person with Long COVID may also have obesity, type 2 diabetes, obstructive sleep apnea, or cardiovascular risk for which a specific FDA-approved GLP-1 or GIP/GLP-1 medication may be appropriate. Treating that condition may improve important health outcomes. It does not prove that the medication is treating Long COVID.

This distinction matters in both clinical care and marketing:

• Better glucose control is not proof that brain fog has resolved.

• Weight loss is not proof of recovery from PEM.

• Improved cardiovascular risk does not establish an antiviral or immune effect.

• A smaller number on the scale does not by itself show improved nourishment, strength, or functional capacity.

Every GLP-1 product has its own approved indications, warnings, contraindications, and dosing instructions. Selection requires evaluation of the exact product and patient, not the drug class in the abstract.

Why GLP-1 Effects Can Complicate Long COVID Tracking

GLP-1 and GIP/GLP-1 medications commonly affect appetite and the gastrointestinal system. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced intake can affect hydration and nutrition. Fatigue and dizziness may also be reported.

Those effects can overlap with Long COVID symptoms or aggravate a person's existing limitations. For someone with dysautonomia, low blood pressure, nausea, gastroparesis-like symptoms, limited fluid intake, or PEM, even a modest change in hydration or nutrition may matter.

Weight loss can include lean tissue as well as fat. A care plan should protect adequate protein, micronutrient intake, hydration, and muscle function within the person's activity tolerance. Standard exercise advice may need adaptation when PEM is present.

Useful baseline information includes:

• Typical food and protein intake

• Fluid and electrolyte strategy

• Nausea, vomiting, constipation, diarrhea, or early fullness

• Weight trajectory and metabolic goals

• Dizziness, heart rate, and orthostatic symptoms

• Current activity ceiling and PEM pattern

• Diabetes medications and hypoglycemia risk

• Kidney, gallbladder, pancreatic, and gastrointestinal history

Starting LDN and a GLP-1 medication at the same time can make it harder to identify which therapy changed sleep, appetite, nausea, bowel function, fatigue, or dizziness. When clinically feasible, staged starts and documented baselines can improve interpretability.

Can LDN and a GLP-1 Be Used Together?

There is no universal rule that automatically prevents every patient from being prescribed LDN with semaglutide or tirzepatide. There is also no clinical evidence establishing the combination as a Long COVID treatment or as a method for enhancing weight loss.

If both are considered, each should have a separate purpose:

• LDN: A clinician-directed off-label trial for a defined symptom target, with uncertain Long COVID efficacy.

• GLP-1 or GIP/GLP-1 therapy: Treatment for the exact approved or otherwise clinically appropriate metabolic indication selected by the prescriber.

The care team should review all prescriptions, over-the-counter medicines, supplements, opioid exposure, planned procedures, diabetes therapy, gastrointestinal symptoms, nutrition, hydration, kidney function where relevant, and pregnancy plans.

LDN is not the same as Contrave, an FDA-approved extended-release product containing naltrexone and bupropion. Evidence for that fixed-dose product cannot be transferred to compounded LDN, and combining products containing naltrexone can unintentionally duplicate therapy.

Read the broader guide to LDN interactions involving opioids, GLP-1s, and other medications.

Opioids, Procedures, and Emergency Planning

Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and may precipitate withdrawal in someone who is physiologically dependent on an opioid. This applies even when the naltrexone dose is described as low.

Patients should tell the prescriber and pharmacist about prescription pain medications, cough or diarrhea products that may contain opioids, medications for opioid use disorder, and any anticipated dental work, surgery, endoscopy, or emergency care.

GLP-1 medications can delay stomach emptying. Current Wegovy and Zepbound labeling instructs patients to tell clinicians before procedures involving anesthesia or deep sedation because retained stomach contents can increase aspiration risk. Review current Wegovy prescribing information and current Zepbound prescribing information.

Patients should not create their own medication-free interval, stop LDN or a GLP-1 before a procedure, or try to overcome opioid blockade without a clinician-directed plan.

For additional safety information, read LDN side effects and opioid considerations.

Where Does Retatrutide Fit?

Retatrutide is an investigational triple hormone-receptor agonist being studied for obesity and related conditions. It is not FDA approved, and there is no established evidence that it treats Long COVID, fatigue, brain fog, PEM, or dysautonomia.

The FDA states that retatrutide cannot be used in compounding under federal law and warns consumers about products sold as “research use only” or “not for human consumption.” Review the FDA's information about unapproved GLP-1 products.

Clinical-trial headlines should not be interpreted as authorization to prescribe, compound, or purchase an investigational ingredient. Review Lilly's current retatrutide information.

Questions to Ask the Prescriber and Pharmacist

1. Which symptom are we trying to improve with LDN?

2. What evidence supports that goal, and what remains uncertain?

3. How will we track fatigue, brain fog, function, and PEM before and after treatment?

4. What dose and titration plan fits my medication sensitivity and health history?

5. When will we decide whether to continue, adjust, or stop?

6. Do any of my medications or products contain an opioid or naltrexone?

7. What is the plan for dental work, surgery, anesthesia, or emergency pain treatment?

8. If a GLP-1 is being considered, what separate metabolic condition is it intended to treat?

9. How will we protect hydration, nutrition, protein intake, and muscle function without provoking PEM?

10. Should LDN and the GLP-1 be started at different times so that benefits and adverse effects can be interpreted?

The Bottom Line

LDN for Long COVID has an evidence signal, not an efficacy verdict. Four observational studies involving 155 participants reported pooled improvements in fatigue, brain fog, sleep, pain, and daily function. No published randomized result has yet established that LDN outperforms placebo, prevents PEM, restores pre-COVID function, or changes the underlying condition.

That does not mean the reports should be dismissed. It means an off-label decision should be honest about uncertainty, tied to a defined symptom target, monitored with a baseline and reassessment plan, and coordinated with the rest of the patient's care.

GLP-1 medications belong in the conversation only when there is a separate metabolic indication and an individualized risk-benefit assessment. They are not proven Long COVID treatments. Appetite, gastrointestinal effects, hydration, nutrition, lean mass, dizziness, and PEM all deserve attention when post-viral illness and metabolic treatment overlap.

Retatrutide remains investigational and cannot be compounded.

Talk With Scripx Pharmacy About a Patient-Specific Prescription

Scripx Pharmacy can help patients and prescribers review a patient-specific compounded LDN prescription, formulation questions, titration instructions, opioid precautions, and coordination with other medications. View LDN information, explore medically supervised weight-management services, or contact Scripx Pharmacy.

LDN use for Long COVID is off label. Compounded medications are not FDA approved. This article is educational and does not diagnose, treat, or replace individualized medical care.

FAQ Package

Is LDN FDA approved for Long COVID?

No. Naltrexone has FDA-approved uses at standard doses for specific alcohol- and opioid-related indications. LDN is an off-label dosing approach, and no naltrexone product is FDA approved to treat Long COVID, fatigue, brain fog, PEM, or dysautonomia. A patient-specific compounded LDN formulation is not FDA approved.

Does LDN help Long COVID fatigue?

Four small observational studies have produced an overall improvement signal for fatigue, but the 2026 systematic review found no randomized controlled trial results and rated the evidence as low certainty. The signal supports further study. It does not prove that LDN caused the improvement or establish how durable the effect is.

Does LDN help brain fog after COVID-19?

Pooled before-and-after scores showed a brain-fog improvement signal. The available studies do not establish objective cognitive benefit, recovery of work or school capacity, or an effect beyond placebo and natural symptom fluctuation. A monitored off-label trial should define what cognitive improvement would mean for the individual.

Does LDN prevent post-exertional malaise?

That has not been established. PEM may cause delayed symptom worsening 12 to 48 hours after exertion and can last days or weeks. Feeling better in the moment should not be interpreted as proof that the risk of a delayed crash has resolved.

How quickly does LDN work for Long COVID?

There is no validated Long COVID timeline. Observational studies used different doses, follow-up periods, outcomes, and co-interventions. A prescriber should set an individualized titration and reassessment plan rather than promise a response by a specific day or week.

What dose of LDN is used for Long COVID?

Studies in the 2026 review used doses from 1 to 6 mg per day, but there is no FDA-approved Long COVID dose and no proven best regimen. Dose, timing, titration, formulation, kidney or liver considerations, medication sensitivity, and the stop plan require patient-specific clinical judgment.

Can LDN be taken with semaglutide or tirzepatide?

There is no universal prohibition against every LDN and GLP-1 combination, but direct combination evidence in Long COVID is lacking. Each medication should have a separate clinical purpose. A prescriber and pharmacist should review gastrointestinal symptoms, nutrition, hydration, dizziness, other diabetes medications, opioid exposure, procedures, and the timing of starts.

Do GLP-1 medications treat Long COVID?

No GLP-1 medication has been established as a treatment for Long COVID, fatigue, brain fog, PEM, or dysautonomia. A specific GLP-1 product may be appropriate for a separate FDA-approved obesity, diabetes, sleep-apnea, or cardiovascular indication after individualized evaluation.

Can LDN interfere with pain medication?

Yes. Naltrexone blocks opioid receptors and can interfere with opioid pain relief. It may precipitate withdrawal in someone who is physiologically dependent on an opioid. Patients should disclose LDN before dental work, surgery, emergency treatment, or any situation in which opioid analgesia may be considered.

Can retatrutide be compounded for Long COVID or weight loss?

No. Retatrutide is investigational and is not FDA approved. The FDA states that retatrutide cannot be used in compounding under federal law. There is also no established evidence that it treats Long COVID.

Medical and Editorial Standards

Medical review process: Scripx Pharmacy develops health content with attention to medical accuracy, scientific clarity, evidence quality, and appropriate discussion of medications, compounded preparations, supplements, and health-related claims. When an article identifies a medical or pharmacy reviewer, that reviewer has evaluated the content within the scope of their professional expertise.

Sources and evidence: Scripx educational content may draw from peer-reviewed research, clinical literature, reputable medical references, professional organizations, and public health or regulatory guidance. References are included when scientific, medical, or health-related claims are discussed. Evidence may evolve, and publication does not mean that every therapy discussed is appropriate for every patient.

Commercial transparency: Scripx Pharmacy provides pharmacy, compounding, and related patient-support services and may offer or facilitate access to products or services discussed in its educational content. Product mentions and links are intended to help readers understand available options and may lead to Scripx product, consultation, or ordering pages. They should not be interpreted as individualized medical advice or a guarantee that treatment will be prescribed or dispensed.

Important disclaimer: This content is for general educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment and does not establish a pharmacist-patient or healthcare provider-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, supplement, or treatment. Prescription medications require an individualized evaluation and, when clinically appropriate, a prescription from a licensed healthcare provider. Compounded medications are prepared for identified patient needs and are not FDA-approved. Individual results and treatment eligibility may vary.